BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 34982354)

  • 41. Evaluation of the EORTC QLQ-C30 questionnaire: a comparison with SF-36 Health Survey in a cohort of Italian long-survival cancer patients.
    Apolone G; Filiberti A; Cifani S; Ruggiata R; Mosconi P
    Ann Oncol; 1998 May; 9(5):549-57. PubMed ID: 9653497
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Normative data for the EORTC QLQ-C30 from the Austrian general population.
    Lehmann J; Giesinger JM; Nolte S; Sztankay M; Wintner LM; Liegl G; Rose M; Holzner B;
    Health Qual Life Outcomes; 2020 Aug; 18(1):275. PubMed ID: 32787854
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Psychometric properties and responsiveness of the EORTC quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer.
    Osoba D; Zee B; Pater J; Warr D; Kaizer L; Latreille J
    Qual Life Res; 1994 Oct; 3(5):353-64. PubMed ID: 7841968
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Patient self-appraisal of change and minimal clinically important difference on the European organization for the research and treatment of cancer quality of life questionnaire core 30 before and during cancer therapy.
    Hong F; Bosco JL; Bush N; Berry DL
    BMC Cancer; 2013 Mar; 13():165. PubMed ID: 23537330
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30) as a measure of psychosocial function in breast cancer patients.
    McLachlan SA; Devins GM; Goodwin PJ
    Eur J Cancer; 1998 Mar; 34(4):510-7. PubMed ID: 9713301
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Validation of the Turkish versions of EORTC QLQ-C30 and BR23 modules in breast cancer patients.
    Demirci S; Eser E; Ozsaran Z; Tankisi D; Aras AB; Ozaydemir G; Anacak Y
    Asian Pac J Cancer Prev; 2011; 12(5):1283-7. PubMed ID: 21875283
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Azeri Version of European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30): Translation and Validation.
    Davudov MM; Harirchi I; Amiraliyev N; Mehtiyeva E; Mirzajani Z; Amiraliyev K; Rustamli N; Zebardast J; Montazeri A
    Asian Pac J Cancer Prev; 2020 Jan; 21(1):267-271. PubMed ID: 31983195
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Interpreting Within-Patient Changes on the EORTC QLQ-C30 and EORTC QLQ-LC13.
    Coon CD; Schlichting M; Zhang X
    Patient; 2022 Nov; 15(6):691-702. PubMed ID: 35771392
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Consistency matters: measurement invariance of the EORTC QLQ-C30 questionnaire in patients with hematologic malignancies.
    Sommer K; Cottone F; Aaronson NK; Fayers P; Fazi P; Rosti G; Angelucci E; Gaidano G; Venditti A; Voso MT; Baccarani M; Vignetti M; Efficace F
    Qual Life Res; 2020 Mar; 29(3):815-823. PubMed ID: 31782016
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Predictive factors of overall well-being using the EORTC QLQ-C15-PAL extracted from the EORTC QLQ-C30.
    Lam K; Zeng L; Zhang L; Tseng LM; Hou MF; Fairchild A; Vassiliou V; Jesus-Garcia R; Alm El-Din MA; Kumar A; Forges F; Chie WC; Sahgal A; Poon M; Chow E
    J Palliat Med; 2013 Apr; 16(4):402-8. PubMed ID: 23458649
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The EORTC CAT Core-The computer adaptive version of the EORTC QLQ-C30 questionnaire.
    Petersen MA; Aaronson NK; Arraras JI; Chie WC; Conroy T; Costantini A; Dirven L; Fayers P; Gamper EM; Giesinger JM; Habets EJJ; Hammerlid E; Helbostad J; Hjermstad MJ; Holzner B; Johnson C; Kemmler G; King MT; Kaasa S; Loge JH; Reijneveld JC; Singer S; Taphoorn MJB; Thamsborg LH; Tomaszewski KA; Velikova G; Verdonck-de Leeuw IM; Young T; Groenvold M;
    Eur J Cancer; 2018 Sep; 100():8-16. PubMed ID: 29936066
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Minimal clinically important differences in the EORTC QLQ-BN20 in patients with brain metastases.
    Wong E; Zhang L; Kerba M; Arnalot PF; Danielson B; Tsao M; Bedard G; Thavarajah N; Cheon P; Danjoux C; Pulenzas N; Chow E
    Support Care Cancer; 2015 Sep; 23(9):2731-7. PubMed ID: 25663577
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mapping the cancer-specific EORTC QLQ-C30 and EORTC QLQ-BR23 to the generic EQ-5D in metastatic breast cancer patients.
    Kim EJ; Ko SK; Kang HY
    Qual Life Res; 2012 Sep; 21(7):1193-203. PubMed ID: 22012023
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mapping EORTC QLQ-C30 and FACT-G onto EQ-5D-5L index for patients with cancer.
    Hagiwara Y; Shiroiwa T; Taira N; Kawahara T; Konomura K; Noto S; Fukuda T; Shimozuma K
    Health Qual Life Outcomes; 2020 Nov; 18(1):354. PubMed ID: 33143687
    [TBL] [Abstract][Full Text] [Related]  

  • 55. General Spanish population normative data analysis for the EORTC QLQ-C30 by sex, age, and health condition.
    Arraras JI; Nolte S; Liegl G; Rose M; Manterola A; Illarramendi JJ; Zarandona U; Rico M; Teiejria L; Asin G; Hernandez I; Barrado M; Vera R; Efficace F; Giesinger JM;
    Health Qual Life Outcomes; 2021 Aug; 19(1):208. PubMed ID: 34461909
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mapping EORTC QLQ-C30 onto EQ-5D for the assessment of cancer patients.
    Kim SH; Jo MW; Kim HJ; Ahn JH
    Health Qual Life Outcomes; 2012 Dec; 10():151. PubMed ID: 23244763
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Summary Score in Patients With Hematologic Malignancies.
    Efficace F; Cottone F; Sommer K; Kieffer J; Aaronson N; Fayers P; Groenvold M; Caocci G; Lo Coco F; Gaidano G; Niscola P; Baccarani M; Rosti G; Venditti A; Angelucci E; Fazi P; Vignetti M; Giesinger J
    Value Health; 2019 Nov; 22(11):1303-1310. PubMed ID: 31708068
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Quality of life of Danish women: population-based norms of the EORTC QLQ-C30.
    Klee M; Groenvold M; Machin D
    Qual Life Res; 1997 Jan; 6(1):27-34. PubMed ID: 9062439
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Correlation between work productivity loss and EORTC QLQ-C30 and -BR23 domains from the MONALEESA-7 trial of premenopausal women with HR+/HER2- advanced breast cancer.
    Tripathy D; Curteis T; Hurvitz S; Yardley D; Franke F; Babu KG; Wheatley-Price P; Im YH; Pencheva R; Eddowes LA; Dionne PA; Chandiwana D; Pathak P; Lanoue B; Harbeck N
    Ther Adv Med Oncol; 2022; 14():17588359221081203. PubMed ID: 35251320
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Estimation of minimally important differences and responder definitions for EORTC QLQ-MY20 scores in multiple myeloma patients.
    Sully K; Trigg A; Bonner N; Moreno-Koehler A; Trennery C; Shah N; Yucel E; Panjabi S; Cocks K
    Eur J Haematol; 2019 Nov; 103(5):500-509. PubMed ID: 31444815
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.